Maresa Altomonte

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo et al. · Annals of Oncology · 2016 · 389 citations · Full text

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Oncology · 2013 · 353 citations

Surgical Oncology, Malignant Disease, Medicine +5

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Anna Maria Di Giacomo, Riccardo Danielli, Massimo Guidoboni et al. · Cancer Immunology Immunotherapy · 2009 · 272 citations · Full text

Systemic Treatments, Tumor Immunology, Medicine +9

Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine

Luca Sigalotti, Elisabetta Fratta, Sandra Coral et al. · Cancer Research · 2004 · 215 citations · Full text

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Luana Calabrò, Aldo Morra, Diana Giannarelli et al. · The Lancet Respiratory Medicine · 2018 · 210 citations

Tumoral Pathology, Medicine, Metronomic Therapy +4